Mirum Pharmaceuticals, Inc. (MIRM) — SEC Financial Statements & Analysis

Mirum Pharmaceuticals, Inc. (MIRM) is a pharmaceutical preparations company, incorporated in DE. Mirum Pharmaceuticals, Inc. trades on Nasdaq as: MIRM. Mirum Pharmaceuticals, Inc. (MIRM)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Mirum Pharmaceuticals, Inc. carries a market cap of $7.42B, a P/E ratio of -8.62x, a P/B ratio of -711.88x, a P/S ratio of 12.00x, an enterprise value of $7.84B, and an EV/EBITDA multiple of -9.70x. On profitability, it posts a gross margin of 81.72%, an operating margin of -134.93%, a net margin of -139.18%, a Return on Equity (ROE) of -702.97%, a Return on Assets (ROA) of -97.15%, and a Return on Invested Capital (ROIC) of -217.79%. Per share, it reports EPS of $-13.57, diluted EPS of $-13.57, free cash flow per share of $-3.61, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 44.02% year-over-year, net income growth of 1368.86% year-over-year, and EPS growth of 1052.55% year-over-year. On the balance sheet, it maintains a current ratio of 2.86x, a quick ratio of 2.62x, working capital of $413.52M, a debt-to-equity ratio of -101.27x, a debt ratio of 1.01, an interest coverage ratio of -62.06x, free cash flow of $-228.74M (TTM), and net debt of $419.35M. Figures sourced from SEC EDGAR.

Market Cap

$7.42B

P/E TTM

-8.62x

EPS TTM

$-13.57

P/B TTM

-711.88x

ROE TTM

-702.97%

ROA TTM

-97.15%

Debt To Equity

-101.27x

Free Cash Flow TTM

$-228.74M

Net Revenue TTM Growth 1Y

44.02%

Data as of 2026-06-30 · Source: SEC EDGAR